CYTOSORBENTS Aktie

>CYTOSORBENTS Aktienkurs

0.465 EUR -2.5% (TradegateBSX)

Ask: 0.526 EUR / 4747 Stück

Bid: 0.493 EUR / 5074 Stück

Tagesumsatz: 9384 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CYTOSORBENTS Aktie über LYNX handeln

Intraday

1 Jahr

>CYTOSORBENTS Performance

1 Woche: -10,1%

1 Monat: -28,5%

3 Monate: -20,9%

6 Monate: -44,4%

1 Jahr: -48,8%

laufendes Jahr: -19,4%

>CYTOSORBENTS Aktie

Name:

CYTOSORBENTS CORP. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US23283X2062 / A12GDU

Symbol/ Ticker:

HQE1 (Frankfurt) / CTSO (NASDAQ)

Kürzel:

FRA:HQE1, ETR:HQE1, HQE1:GR, NASDAQ:CTSO

Index:

Webseite:

http://www.cytosorbents.c..

Profil:

Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSo..
>Volltext..

Marktkapitalisierung:

29.73 Mio. EUR

Unternehmenswert:

49.18 Mio. EUR

Umsatz:

32.11 Mio. EUR

EBITDA:

-10.92 Mio. EUR

Nettogewinn:

-7.1 Mio. EUR

Gewinn je Aktie:

-0.11 EUR

Schulden:

25.22 Mio. EUR

Liquide Mittel:

5.41 Mio. EUR

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

-8.22%

Gewinnwachstum:

65.12%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CYTOSORBENTS

Letzte Datenerhebung:

05.04.26

>CYTOSORBENTS Kennzahlen

Aktien/ Unternehmen:

Aktien: 62.8 Mio. St.

Frei handelbar: 83.38%

Leerverk. Aktien: 3.21%

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 738.01%

Bewertung:

KGV: -

KGV lG: -

KUV: 0.9

KBV: 6.79

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 71.48%

Gewinnmarge: -22.12%

Operative Marge: -38.35%

Managementeffizenz:

Gesamtkaprendite: -17.23%

Eigenkaprendite: -96.39%

>CYTOSORBENTS Peer Group

Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege

>CYTOSORBENTS Chart & Kurs - NASDAQ

>CYTOSORBENTS News

26.03.26 - 16:03	Cytosorbents (CTSO) Q4 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 23:51	Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 22:30	CytoSorbents: Q4-Zahlen enttäuschen, Aktie unter Druck (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:18	Cytosorbents Non-GAAP EPS of -$0.07, revenue of $9.22M beats by $0.01M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 21:09	CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (PR Newswire)
	2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing......

24.03.26 - 22:39	Cytosorbents Q4 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.26 - 14:45	CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 (PR Newswire)
	PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International......

05.03.26 - 13:01	CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (PR Newswire)
	PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year ended December 31, 2025, on......

12.01.26 - 13:03	CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update (PR Newswire)
	Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo......

10.12.25 - 13:01	CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 (PR Newswire)
	PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO,......

18.11.25 - 15:25	CytoSorbents in London: Wachstumspläne und Zulassungsstrategie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

17.11.25 - 23:45	Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
	PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in......

14.11.25 - 01:27	Cytosorbents outlines cash flow breakeven targets for Q1 2026 through workforce and cost restructuring (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 23:42	CytoSorbents-Aktie steigt trotz Umsatzverfehlung nach übertroffenen Gewinnerwartungen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 23:36	Cytosorbents (CTSO) Q3 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 22:15	Cytosorbents Non-GAAP EPS of -$0.04, revenue of $9.5M misses by $0.52M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 22:06	CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million......

11.11.25 - 13:03	CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London (PR Newswire)
	PRINCETON, N.J., Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and......

30.10.25 - 12:03	CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
	PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business......

29.09.25 - 13:03	CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen (PR Newswire)
	PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram